Solid Biosciences (SLDB) Stock Price

Solid Biosciences Price

NASDAQ·CLOSED
9.30USD+0.20 (+2.17 %)
Market closed

Revenue has compounded at 55.8% per year over the past 2 years to 8.09 M USD. Solid Biosciences's net margin stands at -1,062.3%, up from -2,647.4% several years earlier. Analysts set a median price target of 15.30 USD, implying 64.5% above the current price. Of 19 analysts, 18 rate the stock a buy — an overall Buy consensus. The stock trades about 137% above its 52-week low.

Solid Biosciences stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Solid Biosciences over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Solid Biosciences stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Solid Biosciences's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Solid Biosciences Stock Price History
DateSolid Biosciences Price
8/21/20269.30 USD
8/20/20269.10 USD
8/19/20269.56 USD
8/18/20268.89 USD
8/14/20269.20 USD
8/13/20269.08 USD
8/12/20269.06 USD
8/10/20268.56 USD
8/7/20268.39 USD
8/6/20268.71 USD
8/5/20268.66 USD
8/4/20268.56 USD
8/3/20268.02 USD
7/31/20268.06 USD
7/30/20268.49 USD
7/29/20268.07 USD
7/27/20268.00 USD
7/23/20267.98 USD
7/22/20268.10 USD
7/21/20268.46 USD
7/20/20268.45 USD
7/17/20268.72 USD
7/16/20269.05 USD
7/15/20269.62 USD
7/14/20269.63 USD
7/13/20269.67 USD
7/10/202610.42 USD
7/9/202611.14 USD
7/8/202611.27 USD
7/7/202611.15 USD
7/6/202611.11 USD
7/2/202610.84 USD
7/1/202610.20 USD
6/30/20269.99 USD
6/29/20269.47 USD
6/26/20269.29 USD
6/25/20268.86 USD
6/24/20269.25 USD
6/23/20268.79 USD
6/22/20268.31 USD
6/18/20267.60 USD
6/17/20267.40 USD
6/16/20267.08 USD
6/15/20267.41 USD
6/12/20267.17 USD
6/11/20267.01 USD
6/10/20266.79 USD
6/9/20266.57 USD
6/8/20266.41 USD
6/5/20266.76 USD
6/4/20267.28 USD
6/3/20266.82 USD
6/2/20266.75 USD
6/1/20267.26 USD
5/29/20267.39 USD
5/28/20267.11 USD
5/27/20267.08 USD
5/26/20266.74 USD
5/22/20266.43 USD
5/21/20266.44 USD
5/20/20266.41 USD
5/19/20266.08 USD
5/18/20266.51 USD
5/15/20266.92 USD
5/14/20267.63 USD
5/13/20267.38 USD
5/12/20267.72 USD
5/11/20267.68 USD
5/8/20267.27 USD
5/7/20267.07 USD
5/6/20267.20 USD
5/5/20266.90 USD
5/4/20267.23 USD
5/1/20267.13 USD
4/30/20267.26 USD
4/29/20267.05 USD
4/28/20267.45 USD
4/27/20267.50 USD
4/24/20267.92 USD
4/23/20268.32 USD
4/22/20268.40 USD
4/21/20268.16 USD
4/20/20268.49 USD
4/17/20268.63 USD
4/16/20268.39 USD
4/15/20268.32 USD
4/14/20268.23 USD
4/13/20268.39 USD
4/10/20268.02 USD
4/9/20268.10 USD
4/8/20268.02 USD
4/7/20267.74 USD
4/6/20267.74 USD
4/2/20267.49 USD
4/1/20267.38 USD
3/31/20267.20 USD
3/30/20266.49 USD
3/27/20267.11 USD
3/26/20267.73 USD
3/25/20267.23 USD
3/24/20266.68 USD
3/23/20267.14 USD
3/20/20267.03 USD
3/19/20267.12 USD
3/18/20267.12 USD
3/17/20267.76 USD
3/16/20267.48 USD
3/13/20267.31 USD
3/12/20267.71 USD
3/11/20267.72 USD
3/10/20268.18 USD
3/9/20268.02 USD
3/6/20266.75 USD
3/5/20265.61 USD
3/4/20266.14 USD
3/3/20265.96 USD
3/2/20266.20 USD
2/27/20266.21 USD
2/26/20266.29 USD
2/25/20266.31 USD
2/24/20266.18 USD
2/23/20265.87 USD
2/20/20265.71 USD
2/19/20265.88 USD
2/18/20265.92 USD
2/17/20265.50 USD
2/13/20266.19 USD
2/12/20266.08 USD
2/11/20266.40 USD
2/10/20266.93 USD
2/9/20266.86 USD
2/6/20266.52 USD
2/5/20266.23 USD
2/4/20266.52 USD
2/3/20266.54 USD
2/2/20266.43 USD
1/30/20266.46 USD
1/29/20266.60 USD
1/28/20266.55 USD
1/27/20266.57 USD
1/26/20266.45 USD
1/23/20266.60 USD
1/22/20266.86 USD
1/21/20266.16 USD
1/20/20265.62 USD
1/16/20265.47 USD
1/15/20265.66 USD
1/14/20265.81 USD
1/13/20265.16 USD
1/12/20265.24 USD
1/9/20265.29 USD
1/8/20265.31 USD
1/7/20265.61 USD
1/6/20265.49 USD
1/5/20265.33 USD
1/2/20265.45 USD
12/31/20255.64 USD
12/30/20255.70 USD
12/29/20255.69 USD
12/26/20255.84 USD
12/24/20255.90 USD
12/23/20255.90 USD
12/22/20255.98 USD
12/19/20255.94 USD
12/18/20255.28 USD
12/17/20255.38 USD
12/16/20255.82 USD
12/15/20255.71 USD
12/12/20255.87 USD
12/11/20255.87 USD
12/10/20255.88 USD
12/9/20255.75 USD
12/8/20255.71 USD
12/5/20255.77 USD
12/4/20255.92 USD
12/3/20255.19 USD
12/2/20255.10 USD
12/1/20255.21 USD
11/28/20255.43 USD
11/26/20255.36 USD
11/25/20255.15 USD
11/24/20254.91 USD
11/21/20254.70 USD
11/20/20254.46 USD
11/19/20254.48 USD
11/18/20254.47 USD
11/17/20254.34 USD
11/14/20254.24 USD
11/13/20254.30 USD
11/12/20254.74 USD
11/11/20254.53 USD
11/10/20254.15 USD
11/7/20254.06 USD
11/6/20254.22 USD
11/5/20253.93 USD
11/4/20254.41 USD
11/3/20255.20 USD
10/31/20255.39 USD
10/30/20255.31 USD
10/29/20255.49 USD
10/28/20255.92 USD
10/27/20255.90 USD
10/24/20255.62 USD
10/23/20255.52 USD
10/22/20255.64 USD
10/21/20256.01 USD
10/20/20256.15 USD
10/17/20255.88 USD
10/16/20256.16 USD
10/15/20256.32 USD
10/14/20256.23 USD
10/13/20256.01 USD
10/10/20255.96 USD
10/9/20256.40 USD
10/8/20256.31 USD
10/7/20255.52 USD
10/6/20255.48 USD
10/3/20255.90 USD
10/2/20255.74 USD
10/1/20255.87 USD
9/30/20256.17 USD
9/29/20255.97 USD
9/26/20256.15 USD
9/25/20255.92 USD
9/24/20256.24 USD
9/23/20255.33 USD
9/22/20255.17 USD
9/19/20255.12 USD
9/18/20255.44 USD
9/17/20255.47 USD
9/16/20255.41 USD
9/15/20255.49 USD
9/12/20255.39 USD
9/11/20255.31 USD
9/10/20255.24 USD
9/9/20255.00 USD
9/8/20255.13 USD
9/5/20255.50 USD
9/4/20255.56 USD
9/3/20255.75 USD
9/2/20255.43 USD
8/29/20255.48 USD
8/28/20255.62 USD
8/27/20255.62 USD
8/26/20255.71 USD
Access this data via the Eulerpool API
Get Free API Key

Solid Biosciences Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-104.32 M USD
-96.02 M USD
Jan 1, 2024
0.00 USD
-129.73 M USD
-124.70 M USD
Jan 1, 2025
0.00 USD
-179.21 M USD
-174.33 M USD
Jan 1, 2026 (e)
0.00 USD
735,999.00 USD
-137.97 M USD
Jan 1, 2027 (e)
10.87 M USD
2.66 M USD
-136.17 M USD
Jan 1, 2028 (e)
127.62 M USD
25.52 M USD
-104.00 M USD
Jan 1, 2029 (e)
289.48 M USD
57.90 M USD
-2.08 M USD
Jan 1, 2030 (e)
497.05 M USD
99.41 M USD
89.60 M USD

Solid Biosciences Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 2:31 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
–––––3.0013.008.00––––10.00127.00289.00497.00
––––––333.33-38.46–––––1,170.00127.5671.97
–––––-100.00100.00100.00––––-10.00-0.79-0.35-0.20
-1.00-1.00-1.00-1.00-2.00-3.0013.008.00-2.00-2.00-1.00-1.00-1.00-1.00-1.00-1.00
-6.00-25.00-54.00-75.00-119.00-86.00-72.00-106.00-104.00-129.00-179.00–2.0025.0057.0099.00
–––––-2,866.67-553.85-1,325.00––––20.0019.6919.7219.92
-6.00-21.00-52.00-74.00-117.00-88.00-72.00-85.00-96.00-124.00-174.00-137.00-136.00-103.00-2.0089.00
–250.00147.6242.3158.11-24.79-18.1818.0612.9429.1740.32-21.26-0.73-24.26-98.06-4,550.00
94.731.751.282.323.204.717.498.0229.0253.5894.7394.7394.7394.7394.7394.73
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Solid Biosciences generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Solid Biosciences retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Solid Biosciences's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Solid Biosciences has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Solid Biosciences's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Solid Biosciences stock margins

The Solid Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Solid Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Solid Biosciences.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
-530.50 %
-530.01 %
Jan 1, 2022
100.00 %
-1,315.20 %
-1,062.28 %
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
- %
- %
Jan 1, 2027 (e)
100.00 %
24.48 %
-1,253.07 %
Jan 1, 2028 (e)
100.00 %
20.00 %
-81.49 %

Solid Biosciences Stock Revenue, EBIT, Earnings per Share

The Solid Biosciences earnings per share therefore indicates how much revenue Solid Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.82 USD
-9.65 USD
-9.64 USD
Jan 1, 2022
1.01 USD
-13.27 USD
-10.72 USD
Jan 1, 2023
0.00 USD
-3.59 USD
-3.31 USD
Jan 1, 2024
0.00 USD
-2.42 USD
-2.33 USD
Jan 1, 2025
0.00 USD
-1.89 USD
-1.84 USD
Jan 1, 2026 (e)
0.00 USD
0.01 USD
-1.77 USD
Jan 1, 2027 (e)
0.14 USD
0.03 USD
-1.75 USD
Jan 1, 2028 (e)
1.64 USD
0.27 USD
-1.33 USD

Solid Biosciences business model & stock analysis

Solid Biosciences Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Solid Biosciences Employees
Details
Date
Solid Biosciences Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Solid Biosciences Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Solid Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

Solid Biosciences annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Solid Biosciences shares outstanding

The number of shares of Solid Biosciences was 94.73 M in 2025. This indicates how many shares Solid Biosciences is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
7.49 M Stocks
Jan 1, 2022
8.02 M Stocks
Jan 1, 2023
29.02 M Stocks
Jan 1, 2024
53.58 M Stocks
Jan 1, 2025
94.73 M Stocks
Jan 1, 2026 (e)
94.73 M Stocks
Jan 1, 2027 (e)
94.73 M Stocks
Jan 1, 2028 (e)
94.73 M Stocks

Solid Biosciences stock splits

In Solid Biosciences's history, there have been no stock splits.

Current Solid Biosciences forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
94.74 % (18)
Hold
5.26 % (1)
Sell
0.00 % (0)
12M Price Target
15.30
Last Price
9.09
Currency
USD
12M Return Potential
68.32 %
LTM Return
0 %

Solid Biosciences Analyst Rating Actions

DateFirmActionRatingReliability
6/3/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/18/2026
Wedbush
Wedbush
MaintainedOutperform55
5/13/2026
Wedbush
Wedbush
MaintainedOutperform55
5/13/2026
Piper Sandler
Piper Sandler
MaintainedOverweight53
3/25/2026
JP Morgan
JP Morgan
MaintainedOverweight61
3/23/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/20/2026
Needham
Needham
MaintainedBuy70
3/20/2026
Chardan Capital
Chardan Capital
MaintainedBuy–
3/12/2026
Wedbush
Wedbush
MaintainedOutperform55
3/12/2026
Chardan Capital
Chardan Capital
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Solid Biosciences Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.48USD-0.00USD-2026 Q2
5/13/2026-0.44USD-0.00USD-2026 Q1
3/4/2026-0.51USD-0.00USD-2025 Q4
8/11/2025-0.51USD-0.00USD-2025 Q2
11/7/2024-0.68USD-0.00USD-2024 Q3
5/9/2024-1.01USD-1.50 MUSD-2024 Q1
3/21/2024-0.93USD-1.50 MUSD-2023 Q4
11/9/2023-1.08USD-2.23 MUSD-2023 Q3
8/9/2023-0.24USD-2.23 MUSD-2023 Q2
11/10/2022-2.72USD-1.19 MUSD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Solid Biosciences stock

42/100
43
Environment
62
Social
22
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Solid Biosciences shareholder structure

% Name
15.44876%
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
15.28256%
PERCEPTIVE ADVISORS LLC
PERCEPTIVE ADVISORS LLC
12.58994%
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
9.87088%
SIREN, L.L.C.
SIREN, L.L.C.
8.90033%
BLACKROCK, INC.
BLACKROCK, INC.
8.82551%
FMR LLC
FMR LLC
...

Solid Biosciences Beneficial Ownership Filings (SEC 13D/G)

Free Float
79.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
11.90%
Rajeev Shah
Rajeev Shah
SEC ↗
11.90%
RA Capital Management, L.P.
RA Capital Management, L.P.
SEC ↗
11.90%
Peter Kolchinsky
Peter Kolchinsky
SEC ↗
11.80%
RA Capital Healthcare Fund, L.P.
RA Capital Healthcare Fund, L.P.
SEC ↗
11.20%
Perceptive Life Sciences Master Fund, Ltd.
Perceptive Life Sciences Master Fund, Ltd.
SEC ↗
11.20%
Perceptive Advisors LLC
Perceptive Advisors LLC
SEC ↗
11.20%
Joseph Edelman
Joseph Edelman
SEC ↗
11.00%
Oleg Nodelman
Oleg Nodelman
SEC ↗
11.00%
EcoR1 Capital, LLC
EcoR1 Capital, LLC
SEC ↗
11.00%
EcoR1 Capital Fund Qualified, L.P.
EcoR1 Capital Fund Qualified, L.P.
SEC ↗

Solid Biosciences Executives and Management Board

15 members · avg. age 55 · 33 % women

AC

Mr. Alexander Cumbo (54)

President, Chief Executive Officer, Director · since 2022

4.87 M USD

Management

DH

Mr. David Howton (53)

Chief Operating Officer, General Counsel, secretary

2.56 M USD
GB

Dr. Gabriel Brooks (48)

Chief Medical Officer

2.07 M USD
KT

Mr. Kevin Tan (47)

Chief Financial Officer, Treasurer

1.35 M USD
PH

Mr. Paul Herzich (47)

Chief Technology Officer

–
JH

Dr. Jessie Hanrahan (49)

Chief Regulatory Officer

–

Board of Directors

IG

Mr. Ilan Ganot (51)

Co-Founder, Director · since 2013

505,349.00 USD
IS

Mr. Ian Smith (59)

Executive Chairman of the Board · since 2020

449,161.00 USD
MF

Dr. Martin Freed (64)

Independent Director

284,204.00 USD
LS

Ms. Lynne Sullivan (59)

Independent Director

283,204.00 USD
AS

Mr. Adam Stone (45)

Lead Independent Director

279,704.00 USD
SN

Dr. Sukumar Nagendran (59)

Independent Director

276,704.00 USD

Solid Biosciences Supply Chain

Solid Biosciences Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Ultragenyx Pharmaceutical
Supplier·Customer·Biotechnology·US
0.33
0.49
0.64
0.75
0.85
0.88
#NameTrend
1
Thermo Fisher Scientific
Supplier·Customer·Life Sciences Tools & Services·US
0.53
0.73
0.74
0.90
-0.24
-0.47
2
BlackRock
Supplier·Customer·Capital Markets·US
-0.42
0.42
0.92
0.95
0.73
-0.07

Frequently asked questions about Solid Biosciences

Analysts currently set an average price target of 16.04 USD for the Solid Biosciences stock (median: 15.30 USD), implying +76.5 % versus the latest price. The consensus is based on 19 analyst ratings.

Solid Biosciences Analyst Price Targets 2026

19 analysts currently rate the Solid Biosciences stock: 18 recommend buying, 1 holding and 0 selling.

Solid Biosciences Analyst Price Targets 2026

Converted at the current exchange rate, the Solid Biosciences share trades at 7.97 EUR (9.30 USD).

The Solid Biosciences share (SLDB) is listed on 1 stock exchanges, including: NASDAQ (SLDB).

No history available for Solid Biosciences.

The revenue cannot currently be calculated for Solid Biosciences.

The expected profit of Solid Biosciences is -137.97 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Solid Biosciences is currently -6.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Solid Biosciences stock.

The P/S cannot be calculated for Solid Biosciences currently.

The Eulerpool Quality Score for Solid Biosciences is 2/10.

The ISIN of Solid Biosciences is US83422E2046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Solid Biosciences is SLDB. The ticker symbol is used to trade Solid Biosciences shares on the stock exchange.

Solid Biosciences paid dividends every year for the past 0 years.

Solid Biosciences is assigned to the 'Health' sector.

The dividends of Solid Biosciences are distributed in USD.

All fundamentals and in-depth analysis of Solid Biosciences

Our stock analysis for Solid Biosciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Solid Biosciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Solid Biosciences Stock
Solid Biosciences Revenue→
Solid Biosciences Stock
Solid Biosciences Net Income→
Solid Biosciences Stock
Solid Biosciences P/E→
Solid Biosciences Stock
Solid Biosciences P/S→
Solid Biosciences Stock
Solid Biosciences EBIT→
Solid Biosciences Stock
Solid Biosciences Dividend→
Solid Biosciences Stock
Solid Biosciences Directors Dealings→
Solid Biosciences Stock
Solid Biosciences Stocks→
Solid Biosciences Stock
Solid Biosciences Market capitalization→
Solid Biosciences Stock
Solid Biosciences Debt→
Solid Biosciences Stock
Solid Biosciences Liabilities→
Solid Biosciences Stock
Solid Biosciences Equity→
Solid Biosciences Stock
Solid Biosciences AAQS→
Solid Biosciences Stock
Solid Biosciences Employees→
Solid Biosciences Stock
Solid Biosciences ROE→
Solid Biosciences Stock
Solid Biosciences ROA→
Solid Biosciences Stock
Solid Biosciences ROCE→
Solid Biosciences Stock
Solid Biosciences News→
Solid Biosciences Stock
Solid Biosciences Analyst Price Targets→

Health Stocks

SoligenixSolbornSomnomedSolastoSona NanotechSolasia Pharma KKSonendoSolara Active Pharma SciencesSonic HealthcareSolanaSonida Senior LivingSOL Global InvestmentsAll Stocks A–Z →